Abstract 23P
Background
Breast cancer is the second most common cancer in women worldwide and contributes to a significant amount of mortality annually. It also contributes significantly to cancer-related morbidity in Bali especially in Gianyar district where most of the breast cancers are diagnosed at an advanced stage. Therefore, we aimed to evaluate the correlation between the levels of knowledge with the attitude of local-productive age women toward SADARI (breast self-assessment).
Methods
A family-based cross-sectional study was conducted in August 2018 in the Pejeng Kaja village, Ubud, Bali. The level of knowledge such as the definition of breast cancer, risk factors, therapy, prevention and several aspects of SADARI method was examined using a validated questionnaire. All of the data were subsequently recorded into SPSS for analysis.
Results
122 respondents were enrolled in this study with a mean age of 45.65±9.51 years. More than half of the respondents were having at least high school education and 55% know breast cancer. However, 46.7% were known about SADARI. 5 variables were significantly associated with the status of SADARI knowledge namely: level of education, knowledge about breast cancer, breast cancer prevention, and how to perform SADARI as well as the frequency of SADARI performance by respondents (p < 0.05). Risk assessment for each variable showed that all variables had OR > 5 with the biggest OR on the level of education (OR: 7.2; 95%CI: 3.56-14.75).
Conclusions
We conclude that the level of education, knowledge about breast cancer, early symptoms of breast cancer, breast cancer prevention, and how to perform SADARI as well as frequency of SADARI performance influenced the performance rate of SADARI in reproductive women in Pejeng Kaja with low level of education posed the greatest risk of not performing SADARI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract